rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Michael Raab

President & CEO

Company insider

Files Form 4 as: President & CEO, Ardelyx; Director, Amicus Therapeutics; Director, Tempest Therapeutics; Director, Novacea.

Every Form 4 they filed

In numbers

Trades disclosed
274
Buys
1
Sells
77
Bought
$1,860
Sold
$11.7M
Companies
4
Companies where not an officer
3
First trade
17 Jan 2007
Last trade
21 Aug 2026
Last filed
25 Aug 2026

Companies traded

Where they are an officer
ARDX ArdelyxDirector, Officer · Biotechnology · last 21 Aug 20261 buy · 70 sells
Everywhere else they filed: board seats, 10% stakes, other companies
Amicus TherapeuticsDirector · Biotechnology · last 27 Apr 20260 buys · 7 sells
TPST Tempest TherapeuticsDirector · Biotechnology · last 27 Jan 20260 buys · 0 sells
NovaceaDirector · last 13 Feb 20080 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
30Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
21 Aug 2026filed 25 Aug 2026ARDX ArdelyxBiotechnologySEC FORM 4 Sold$58K15,009 at $3.86filing
21 Aug 2026filed 25 Aug 2026ARDX ArdelyxBiotechnologySEC FORM 4 Sold$62K15,976 at $3.86filing
21 Aug 2026filed 25 Aug 2026ARDX ArdelyxBiotechnologySEC FORM 4 Sold$32K8,411 at $3.86filing
21 Aug 2026filed 25 Aug 2026ARDX ArdelyxBiotechnologySEC FORM 4 Sold$74K19,178 at $3.86filing
21 Aug 2026filed 25 Aug 2026ARDX ArdelyxBiotechnologySEC FORM 4 Sold$58K15,009 at $3.86filing
21 Aug 2026filed 25 Aug 2026ARDX ArdelyxBiotechnologySEC FORM 4 Sold$62K15,976 at $3.86filing
21 Aug 2026filed 25 Aug 2026ARDX ArdelyxBiotechnologySEC FORM 4 Sold$32K8,411 at $3.86filing
21 Aug 2026filed 25 Aug 2026ARDX ArdelyxBiotechnologySEC FORM 4 Sold$74K19,178 at $3.86filing
15 Jul 2026filed 17 Jul 2026ARDX ArdelyxBiotechnologySEC FORM 4 Code M$21K20,834 at $0.99filing
15 Jul 2026filed 17 Jul 2026ARDX ArdelyxBiotechnologySEC FORM 4 Sold$211K41,668 at $5.06filing
15 Jul 2026filed 17 Jul 2026ARDX Ardelyxoption or derivative · BiotechnologySEC FORM 4 Code M—20,834 at $0.00filing
15 Jul 2026filed 17 Jul 2026ARDX Ardelyxoption or derivative · BiotechnologySEC FORM 4 Code M—20,834 at $0.00filing
15 Jul 2026filed 17 Jul 2026ARDX ArdelyxBiotechnologySEC FORM 4 Code M$21K20,834 at $0.99filing
15 Jul 2026filed 17 Jul 2026ARDX ArdelyxBiotechnologySEC FORM 4 Sold$211K41,668 at $5.06filing
15 Jun 2026filed 17 Jun 2026ARDX ArdelyxBiotechnologySEC FORM 4 Code M$21K20,833 at $0.99filing
15 Jun 2026filed 17 Jun 2026ARDX ArdelyxBiotechnologySEC FORM 4 Sold$236K41,666 at $5.67filing
15 Jun 2026filed 17 Jun 2026ARDX Ardelyxoption or derivative · BiotechnologySEC FORM 4 Code M—20,833 at $0.00filing
15 Jun 2026filed 17 Jun 2026ARDX Ardelyxoption or derivative · BiotechnologySEC FORM 4 Code M—20,833 at $0.00filing
15 Jun 2026filed 17 Jun 2026ARDX ArdelyxBiotechnologySEC FORM 4 Code M$21K20,833 at $0.99filing
15 Jun 2026filed 17 Jun 2026ARDX ArdelyxBiotechnologySEC FORM 4 Sold$236K41,666 at $5.67filing

Sectors

Health Care71
Not placed7

Buys in green, sells in red, by the company’s sector.

Related people

Susan HohenleitnerChief Financial Officer · Chief Financial Officer at Ardelyx, filing Form 4 there in the last year
John E. BishopOfficer · Officer at Ardelyx, filing Form 4 there in the last year
Laura A. WilliamsChief Patient Officer · Chief Patient Officer at Ardelyx, filing Form 4 there in the last year
Mike KelliherChief Business Officer · Chief Business Officer at Ardelyx, filing Form 4 there in the last year
Eric Duane FosterChief Commercial Officer · Chief Commercial Officer at Ardelyx, filing Form 4 there in the last year
James Parker BradyChief Human Resources Officer · Also traded ARDX in the last 90 days
Joseph James ReillyOfficer · Also traded ARDX in the last 90 days